Affiliation:
1. Discipline of Medical Sciences, School of Science, Western Sydney University, NSW 2751, Australia
2. Department of
Pharmacology, NICM-Health Research Institute, Western Sydney University, NSW 2751, Australia
3. Department of Community Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz,
I.R. Iran
Abstract
Background and Aims:
Curcumin is one of the most commonly used indigenous molecules endowed
with various shielding functionalities that protect the liver. In the present research, we aimed to investigate
the effects of curcumin on metabolic factors and body mass index (BMI) in patients with non-alcoholic fatty
liver disease (NAFLD) using a meta-analysis of randomized, controlled trials.
Methods::
Online databases PubMed, Embase, Web of Science, and Science Direct were searched until April
2021 to identify eligible articles. Fourteen trials were included.
Results:
The results showed that curcumin consumption can significantly reduce AST (-0.35, (-0.57 to
-0.14)), total cholesterol (-0.81, (-1.34 to -0.27)), TG (-0.49, (-0.71 to -0.27)), and FBS (-0.28, (-0.46 to -0.09))
in patients with NAFLD. However, the improvements in ALT (-0.29, (-0.58 to 0.00)), LDL (-0.48, (-0.97 to
0.01)), HDL (0.03, (-0.38 to 0.44)), and BMI (-0.13, (-0.29 to 0.02)) were not statistically significant. Furthermore,
the findings revealed that the optimal dose and duration of curcumin consumption for patients with
NAFLD is <500 mg/d for less than 10 weeks.
Conclusions:
The present study suggests that consuming curcumin can improve liver enzymes, lipid profile,
FBS, and BMI in patients with NAFLD. Moreover, curcumin supplementation may provide beneficial effects
on metabolic biomarkers and body weight if used at the appropriate dose and duration. Further RCTs are
required to confirm our findings.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献